IP Library Granted Patent US 7,829,084
Granted Patent B2
US 7,829,084 · App. 10/627,556 · Granted Nov 9, 2010

Binding constructs and methods for use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,829,084
App. No.
10/627,556
Granted
Nov 9, 2010
Kind
B2
Abstract

The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type IgG1, IGA or IgE hinge-acting region, i.e., IgE CH2, region polypeptide or a mutant IgG1 hinge region polypeptide having either zero, one or two cysteine residues, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins.

Claims (13)

1. A non-naturally occurring single chain Fv protein comprising:

i) a first polypeptide having a G28-1 single chain Fv binding domain polypeptide, said binding domain polypeptide comprising a light chain variable region and a heavy chain variable region, wherein a serine is at position 11 in the first framework region of the heavy chain variable region;

ii) a second polypeptide comprising an altered wild type IgG1 immunoglobulin hinge region attached to said first polypeptide, wherein the wild type IgG1 hinge region comprises first, second and third cysteine residues and a proline, wherein the first cysteine is N-terminal to the second cysteine, the second cysteine is N-terminal to the third cysteine, and the third cysteine is N-terminal to the proline, and wherein in the altered hinge region said first and second cysteine residues are substituted with serine and said proline residue is substituted with serine; and

iii) a third polypeptide comprising an N-terminally truncated immunoglobulin heavy chain constant region polypeptide attached to the second polypeptide, wherein said heavy chain constant region comprises CH2 and CH3 domains from IgG 1 .

2. A non-naturally occurring single chain Fv protein comprising:

i) a first polypeptide having a G28-1 single chain Fv binding domain polypeptide, said binding domain polypeptide comprising a light chain variable region and a heavy chain variable region, wherein a serine is at position 11 in the first framework region of the heavy chain variable region;

ii) a second polypeptide comprising an altered wild type IgG1 immunoglobulin hinge region attached to said first polypeptide, wherein the wild type IgG1 hinge region comprises first, second and third cysteine residues and a proline, wherein the first cysteine is N-terminal to the second cysteine, the second cysteine is N-terminal to the third cysteine, and the third cysteine is N-terminal to the proline, and wherein in the altered hinge region, said second cysteine residue is substituted with serine and said proline residue is substituted with serine, and

iii) a third polypeptide comprising an N-terminally truncated immunoglobulin heavy chain constant region polypeptide attached to the second polypeptide, wherein said heavy chain constant region comprises CH2 and CH3 domains from IgG 1 .

3. A non-naturally occurring single chain Fv protein comprising:

i) a first polypeptide having a G28-1 single chain Fv binding domain polypeptide, said binding domain polypeptide comprising a light chain variable region and a heavy chain variable region, wherein a serine is at position 11 in the first framework region of the heavy chain variable region;

ii) a second polypeptide comprising an altered wild type IgG1 immunoglobulin hinge region attached to said first polypeptide, wherein the wild type IgG1 hinge region comprises first, second and third cysteine residues and a proline, wherein the first cysteine is N-terminal to the second cysteine, the second cysteine is N-terminal to the third cysteine, and the third cysteine is N-terminal to the proline, and wherein the altered hinge region said first and second cysteine residues are substituted with serine,

iii) a third polypeptide comprising an N-terminally truncated immunoglobulin heavy chain constant region polypeptide attached to the second polypeptide, said heavy chain constant region comprising CH2 and CH3 domains from IgG 1 .

4. A single chain protein comprising amino acids 21-493 as set forth in SEQ ID NO:326, 328, 330, 374, 376 or 378.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Mar 6, 2020
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: APTEVO THEAPEUTICS INC.; APTEVO BIOTHERAPEUTICS LLC; APTEVO RESEARCH AND DEVELOPMENT LLC
Reel/Frame 052039/0258 →
SECURITY INTEREST Recorded Feb 7, 2019
From: APTEVO THERAPEUTICS INC.; APTEVO BIOTHERAPEUTICS INC.; APTEVO RESEARCH AND DEVELOPMENT LLC
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 048270/0813 →
CHANGE OF NAME Recorded Jul 18, 2016
From: EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLC
To: APTEVO RESEARCH AND DEVELOPMENT LLC
Reel/Frame 039382/0985 →
MERGER Recorded Dec 21, 2010
From: TRUBION PHARMACEUTICALS, INC.
To: EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLC
Reel/Frame 025541/0845 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2004
From: LEDBETTER, JEFFREY A.; LEDBETTER, MARTHA S.; THOMPSON, PETER A.
To: TRUBION PHARMACEUTICALS, INC.
Reel/Frame 015319/0819 →